CO5670356A2 - Programa de dosificaicon para un nuevo agente anticanceroso - Google Patents

Programa de dosificaicon para un nuevo agente anticanceroso

Info

Publication number
CO5670356A2
CO5670356A2 CO06015089A CO06015089A CO5670356A2 CO 5670356 A2 CO5670356 A2 CO 5670356A2 CO 06015089 A CO06015089 A CO 06015089A CO 06015089 A CO06015089 A CO 06015089A CO 5670356 A2 CO5670356 A2 CO 5670356A2
Authority
CO
Colombia
Prior art keywords
inhibitor
new anti
mammal
interval
procedure
Prior art date
Application number
CO06015089A
Other languages
English (en)
Spanish (es)
Inventor
Samit Kumar Bhattacharya
Richard Damian Connell
James Dale Moyer
Jitseh Pranlal Jani
Dennis Alan Noe
Stefanus Johannes Steyn
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CO5670356A2 publication Critical patent/CO5670356A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO06015089A 2003-08-18 2006-02-15 Programa de dosificaicon para un nuevo agente anticanceroso CO5670356A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49591903P 2003-08-18 2003-08-18

Publications (1)

Publication Number Publication Date
CO5670356A2 true CO5670356A2 (es) 2006-08-31

Family

ID=34193358

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06015089A CO5670356A2 (es) 2003-08-18 2006-02-15 Programa de dosificaicon para un nuevo agente anticanceroso

Country Status (18)

Country Link
US (1) US20050119288A1 (enExample)
EP (1) EP1658080A1 (enExample)
JP (1) JP2007502807A (enExample)
KR (2) KR20080014144A (enExample)
CN (1) CN1838959A (enExample)
AR (1) AR045268A1 (enExample)
AU (1) AU2004264726A1 (enExample)
BR (1) BRPI0413745A (enExample)
CA (1) CA2536140A1 (enExample)
CO (1) CO5670356A2 (enExample)
IL (1) IL173127A0 (enExample)
MX (1) MXPA06001989A (enExample)
NO (1) NO20061252L (enExample)
RU (1) RU2328287C2 (enExample)
SG (1) SG135193A1 (enExample)
TW (1) TW200522966A (enExample)
WO (1) WO2005016347A1 (enExample)
ZA (1) ZA200600517B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0307544A (pt) 2002-02-01 2004-12-07 Ariad Gene Therapeutics Inc Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos
US8505468B2 (en) * 2002-11-19 2013-08-13 Sharp Kabushiki Kaisha Substrate accommodating tray
JP4828421B2 (ja) * 2003-08-14 2011-11-30 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
MXPA06003113A (es) 2003-09-19 2006-06-20 Astrazeneca Ab Derivados de quinazolina.
AP2204A (en) * 2004-05-06 2011-02-07 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides.
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
EP1896030A1 (en) * 2005-06-03 2008-03-12 Pfizer Products Incorporated Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
JP5235662B2 (ja) * 2005-06-16 2013-07-10 ミリアド ジェネティクス， インコーポレイテッド 薬学的組成物およびその使用
JP2009502960A (ja) * 2005-07-27 2009-01-29 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム 膵臓癌の処置のためのゲムシタビンおよびチロシンキナーゼ阻害剤を含む組み合わせ
US8945573B2 (en) * 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
CN102579467A (zh) * 2005-11-14 2012-07-18 阿里亚德医药股份有限公司 雷帕霉素衍生物在治疗癌症中的用途
CA2755268C (en) * 2005-11-15 2013-12-31 Array Biopharma, Inc. Erbb inhibitors
AU2007241130A1 (en) * 2006-03-31 2007-11-01 EMD Serono Research Centre, Inc. Treatment of tumors expressing mutant EGF receptors
WO2007115286A2 (en) * 2006-04-05 2007-10-11 Novartis Ag. Combinations of therapeutic agents for treating cancer
CA2669415A1 (en) 2006-11-14 2008-05-22 Ariad Pharmaceuticals, Inc. Solid dosage form comprising ap23573
NZ580868A (en) * 2007-04-10 2011-07-29 Myriad Pharmaceuticals Inc Dosages and methods for the treatment of cancer
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
KR20100016385A (ko) * 2007-04-10 2010-02-12 미리어드 파마슈티칼스, 인코포레이티드 뇌종양 치료방법
AU2008236997A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Methods for treating cancer
EP2144886A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc METHOD OF TREATING MELANOMA
CA2690334C (en) * 2007-06-08 2017-02-14 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
US8252805B2 (en) * 2008-05-07 2012-08-28 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
WO2010027848A2 (en) * 2008-08-26 2010-03-11 Teva Pharmaceutical Industries Ltd. Forms of lapatinib compounds and processes for the preparation thereof
SG10201402742YA (en) 2009-03-20 2014-08-28 Genentech Inc Bispecific anti-her antibodies
US20130209543A1 (en) * 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
CN110564604B (zh) 2014-01-31 2023-09-29 凸版印刷株式会社 液滴的形成方法、生物分子分析方法及生物分子分析试剂盒
HK1259311A1 (zh) * 2015-10-28 2019-11-29 Tva (Abc), Llc Sstr靶向綴合物及其顆粒和製劑

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA932522B (en) * 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DE69536015D1 (de) * 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
NZ522568A (en) * 2000-06-22 2004-12-24 Pfizer Prod Inc Substituted bicyclic derivatives for the treatment of abnormal cell growth
AP2004003059A0 (en) * 2001-12-12 2004-06-30 Pfizer Prod Inc Salt forms of E-2-methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxyl)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
IL161908A0 (en) * 2001-12-12 2005-11-20 Pfizer Prod Inc Quinazoline derivatives for the treatment of abnormal cell growth
EP1567506A4 (en) * 2002-11-20 2007-06-20 Array Biopharma Inc CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR
EP1575592A1 (en) * 2002-12-18 2005-09-21 Pfizer Products Inc. 4-anilino quinazoline derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
AU2004264726A1 (en) 2005-02-24
BRPI0413745A (pt) 2006-10-24
EP1658080A1 (en) 2006-05-24
KR20080014144A (ko) 2008-02-13
CN1838959A (zh) 2006-09-27
NO20061252L (no) 2006-05-16
RU2006102125A (ru) 2007-09-27
KR20060037447A (ko) 2006-05-03
SG135193A1 (en) 2007-09-28
AR045268A1 (es) 2005-10-19
US20050119288A1 (en) 2005-06-02
CA2536140A1 (en) 2005-02-24
RU2328287C2 (ru) 2008-07-10
IL173127A0 (en) 2006-06-11
ZA200600517B (en) 2007-02-28
WO2005016347A1 (en) 2005-02-24
MXPA06001989A (es) 2006-05-17
JP2007502807A (ja) 2007-02-15
TW200522966A (en) 2005-07-16

Similar Documents

Publication Publication Date Title
AR109995A2 (es) Método para inhibir la resorción ósea
EA201070740A1 (ru) Способ лечения перелома кости антителами против склеростина
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
AR039416A1 (es) Un metodo para prevenir y/o tratar el rechazo cronico en un organo o un tejido transplantado
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
EA200400966A1 (ru) Новые лекарственные формы замещенного бензимидазола и способ их применения
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
MX9702527A (es) Metodo y composicion de sintesis de oxido nitrico estimulante.
AR060089A1 (es) Tratamiento del dolor
ECSP056156A (es) Procedimiento y composiciones farmacéuticas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
PE20080349A1 (es) Estructuras de cristal de inhibidores sglt2 y procesos para preparar los mismos
BR0111800A (pt) Combinações de inibidores de depeptidil peptidase iv e outros agentes antidiabéticos para o tratamento de diabete mellitus
CR10627A (es) Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4
AR051446A1 (es) Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
AR083957A1 (es) Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica
BRPI0919020A2 (pt) Uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
EA200200324A1 (ru) Способы применения селективных ингибиторов обратного захвата серотонина быстрого запуска для лечения половой дисфункции
EP2512479A4 (en) METHOD AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
CO5590913A2 (es) Terapia de combinacion antivirica
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
BRPI0413745A (pt) horário mde dosagem para agentes anticancerìgenos erbb2
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
BR0313718A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction

Legal Events

Date Code Title Description
FC Application refused